Eventide Asset Management Acquires 7.3% Stake in Ovid Therapeutics Inc. (OVID)

On May 15, 2026, Eventide Asset Management, LLC filed a Schedule 13G disclosing a new 7.3% stake in Ovid Therapeutics Inc. (OVID). The filing reflects the beneficial ownership of 12,773,577 shares of Common Stock as of the event date on March 31, 2026. This position is held primarily through the Eventide Healthcare & Life Sciences Fund, for which Eventide Asset Management serves as the investment adviser. The filing was made jointly with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, who are associated with Eventide and share voting and dispositive power over the reported shares. Previously, the filers reported no holdings (0.0%), marking a significant new entry into the issuer's equity. The reported securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Eventide Asset Management is a Delaware-based investment adviser located in Boston, Massachusetts.